Клинико-патогенетическая гетерогенность рассеянного склероза
Диссертация
Апробация работы. Материалы диссертации доложены и обсуждены на юбилейной конференции Северо-Западной ассоциации рассеянного склероза (Санкт-Петербург, 2001), на VIII Всероссийском съезде неврологов (Казань, 2001), на 9th International Symposium of the Japan-Russia Medical Exchange (Kanazava, Japan, 2001) — на региональной научно-практической конференции «Здоровье женщины старше 40 лет» (Томск… Читать ещё >
Список литературы
- Абрамов, В.В. Принципы нейроиммунологии в эксперименте и клинике / В. В. Абрамов // Иммунология. 1995. — № 6. — С. 11−16.
- Акимов, Г. А. Мультифакториальность патогенеза и иммуноэндокринная модуляция рассеянного склероза. / Г. А. Акимов, В. И. Головкин // Журн. невропатол. и психиатр. 1987. — Т. 87, № 2. — С. 199−203.
- Алифирова, В.М. Некоторые закономерности и механизмы нарушений гомеостатического баланса при демиелинизирующих заболеваниях и церебральном арахноидите : автореф. дис.. д-ра мед. наук / В. М. Алифирова. СПб, 1999. — 40 с.
- Бойко, А.Н. Рассеянный склероз: молекулярные и клеточные механизмы / А. Н. Бойко, О. О. Фаворова. // Молекулярная биология. 1995. — Т .29, № 4. — С. 727−749.
- Варианты течения и прогноз при рассеянном склерозе / Е. И. Гусев, А. Н. Бойко, В. А. Силуянова и др. // Рассеянный склероз и другиедемиелинзирующие заболевания / под ред. Е. И. Гусева, И. А. Завалишина,
- A.Н. Бойко. М.: Миклош, 2004. — С. 158−180.
- Н.Горбунов, В. И. Иммунология травматической болезни головного мозга /
- B.И. Горбунов, Л. Б. Лихтерман, И. В. Ганнушкина. Ульяновск, 1996. -558 с.
- З.Гусев, Е. И. Патогенетическое лечение рассеянного склероза / Е. И. Гусев, А. Н. Бойко // Рассеянный склероз и другие демиелинизирующие заболевания / ред. Е. И. Гусев, И. А. Завалишин, А. Н. Бойко. М.: Миклош, 2004. — С. 356−384.
- Гусев, Е.И. Рассеянный склероз / Е. И. Гусев, Т. Л. Демина, А. Н. Бойко. -М.: Нефть и газ, 1997. 463 с.
- Интерфероновый статус при рассеянном склерозе / С. Б. Чекнев, O.JI. Латышева, О. И. Тункель и др. // Иммунология. 1990. — № 6. — С. 57−60.
- К вопросу о демиелинизирующих заболеваниях в Иркутской области / И. И. Кожова, В. В. Берденникова, В. В. Бардымов, О. И. Юрьева // Материалы пленума правления Российского общества неврологов. -Иркутск, 1992.-С. 119−121.
- Команденко, Н.И. Патогенетические механизмы развития экспериментального аллергического полирадикулоневрита / Н. И. Команденко, В. М. Алифирова // Журн. неврол. и психиатр. 1995. — Т. 95, № 2.-С. 41−46.
- Лакин, Г. Ф. Биометрия. М.: Высшая школа. — 1990. — 352 с.
- Малкова, Н.А. Течение рассеянного склероза в Западной Сибири (на прим. г. Новосибирска): автореф. дис. канд. мед. наук / Н. А. Малкова. -Новосибирск, 1988. 18 с.
- Марков, Д.А. Рассеянный склероз / Д. А. Марков, А. Л. Леонович. М.: Медицина, 1976. — 296 с.
- Мишанькин, Б.Н. Суперантигены актуальная проблема современной иммунологии / Б. Н. Мишанькин, Г. И. Васильева // Иммунология. — 1996. -№ 3.-С. 10−14.
- Морлей, Дж. Лимфокины / Дж. Морлей, Дж. Хансон, В. М. Румьянек // Руководство по иммунофармакологии: пер. с англ. / под ред. М. М. Дейла, Дж.К. Формана. М.: Медицина, 1998. — С. 149−160.
- Мур, М. Интерфероны / М. Мур, М. М. Даусон // Руководство по иммунофармакологии: пер. с англ. / под ред. М. М. Дейла, Дж.К. Формена. М.: Медицина, 1998. — С. 292−306.
- Панов, А.Г. Диагностика рассеянного склероза и энцефаломиелита / А. Г. Панов, А. П. Зинченко. Л.: Медицина, 1970. — 239 с.
- Посвалюк, Н.Э. Клинико-эпидемиологическая характеристика рассеянного склероза в Хабаровском крае / Н. Э. Посвалюк, Т. А. Козлова, А. Г. Цеферман // Рассеянный склероз (эпидемиология, новые методы диагностики): Сб. науч. тр. Новосибирск, 1985. — С. 10−12.
- Простой и быстрый метод определения делеции 32 пн в гене рецептора хемокинов CCR5 / П. А. Сломинский, М. И. Шадрина, В. А. Спицын и др. // Генетика. 1997. — Т. 33, № 11. — С. 1596−1598.
- Распространенность делеции 32 пн в гене рецептора хемокинов CCR5 в популяциях Волго-Уральского Регина / А. Р. Галеева, Э. К. Хаснутдинова, П. А. Сломинский, С. А. Лимборская // Генетика. 1998. -Т. 34, № 8. — С. 1160−1162.
- Рассеянный склероз: нейроиммунопатогенез, иммунодиагностика и иммунотерапия / И. Д. Столяров, A.M. Петров, Е. В. Ивашкова и др. // Нейроиммунология. 2003. — Т. 1, № 1. — С. 32−37.
- Результаты открытых пострегистрационных клинических испытаний препарата копаксон у больных рассеянным склерозом / И. А. Завалишин, Е. И. Гусев, Н. Н. Яхно и др. // Рассеянный склероз: прил. к «Журн. неврол. и психитар. 2002. — Спец. Вып. — С. 8−12.
- Ройт, А. Иммунология : пер. с англ / А. Ройт, Дж. Бростофф, Д. Мейл. М.: Мир, 2000. — 592 с.
- Сравнительный анализ клинико-демографических параметров PC с ранним дебютом в двух популяциях (Москва, Россия и Ванкувер, Канада) / А. Н. Бойко, О. В. Быкова, С. Н. Федосова и др. // Нейроиммунология. -2003. -№ 1,-С. 38−44.
- Сравнительный клинико-иммунохимический анализ ремиттирующего и вторично-прогрессирующего течения рессеянного склероза / Е. И. Гусев,
- И.А. Беляева, В. П. Чехонин и др. // Журн. неврол. и психиатр. 2000. — Т. 100, № 6.-С. 51−57.
- Тимаков, В.Д. Медленные инфекции / В. Д. Тимаков, В. А. Зуев. М.: Медицина, 1977. — 279 с.
- Фильченков, А.А. Апоптоз и рак / А. А. Фильченков, Р. С. Стойка. Киев.: Морион, 1999. — 184 с.
- Ходос, Х.Г. Рассеяный склероз / Х. Г. Ходос, И. И. Кожова. Иркутск: Восточно-Сибирское книжное изд-во, 1980. — 176 с.
- Хондкариан, О.А. Рассеянный склероз / О. А. Хондкариан, И. А. Завалишин, О. М. Невская. М.: Медицина, 1987. — 256 с.
- Цитокины в иммунопатогенезе рассеянного склероза / Т. Л. Демина, Е. И. Гусев, А. Н. Бойко, Б. В. Пинегин // Журн. неврол. и психиатр. 1997. — Т. 97, № 5. — С. 68−73.
- А full genome search in multiple sclerosis / G.C. Ebers, K. Kukay, D.E. Bulman et al. //Nat. Genet. 1996. — Vol. 13. — P. 472−476.
- A functional and structural basis for TCR cross-reactivity in multiple sclerosis / H.L.E. Lang, H. Jacobsen, S. Ikemizu et al. // Nat. Immunol. 2002. — Vol. 3. -P. 940−943.
- A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22 / S. Sawcer, H.B. Jones, R. Feakes et al. // Nat. Genet. 1996. — Vol. 13. — P. 464−468.
- A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis / E.S. Huseby, D. Liggitt, T. Brabb et al. // J. Exp. Med. 2001. — Vol. 194, N 5. — P. 669−676.
- A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis /М.В. Bornstein, A. Miller, S. Slage et al. //Neurology. 1991. — Vol. 41. — P. 533−539.
- A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: A study of 113 cases / C. Lucchinetti, W. Bruck, J. Parisi et al. // Brain. 1999. -Vol. 122. — P. 2279−2295.
- A randomized, double-blind, dose-comparison study of weekly interferon (3−1 a in relapsing MS / M. Clanet, E.W. Radue, L. Kappos et al. // Neurology. 2002. -Vol. 59.-P. 1507−1517.
- A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica / C.F. Lucchinetti, R.N. Mandler, D. McGavern et al. // Brain. 2002. -Vol. 125.-P. 1450−1461.
- A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro / F. Pociot, J. Molvig, L. Wogensen et al. //Eur. J. Clin. Inves. 1992. — Vol. 22. — P. 396−402.
- Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation / A. Bitsch, J. Schuchardt, S. Bunkowski et al. // Brain. 2000. -Vol. 123.-P. 1174−1183.
- Aloisi, F. Regulation of T cell responses by central nervous system antigen presenting cells: different roles for microglia and astrocytes / F. Aloisi, F. Ria, L. Adorini // Immunol. Today. 2000. — Vol. 3. — P. 141−147.
- Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis / R. Egg, M. Reindl, F. Deisenhammer et al. // Mult Scler. 2001. — Vol. 7. — P. 285 -289.
- AntimyeIin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event / T. Berger, P. Rubner, F. Schautzer et al. // N. Engl. J. Med. 2003. — Vol. 349. — P. 139−145.
- Archelos, J.J. The role of integrins in immune-mediated diseases of the nervous system / J.J. Archelos, S.C. Previtali, H.-P. Hartung // Trends Neurosci. 1999. — Vol. 22. — P. 30−38.
- Arend, W.P. Biological role of interleukin 1 receptor antagonist isoforms / W.P. Arend, C.J. Guthridge // Ann. Rheum. Dis. 2000. — Vol. 59. — P. 60−64.
- Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with disease severity in MS / H.M. Schrijver, J.B. Crusius, B.M. Uitdehaad et al. //Neurology. 1999. — Vol. 52, N 3. — P. 595−599.
- Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians / M.J. Carter, F.S. di Giovine, S. Jones et al. // Gut. 2001. — Vol. 48. — P. 461—467.
- Association of two variants in IL-lbeta and IL-1 receptor antagonist genes with multiple sclerosis / O.H. Kantarci, E.J. Atkinson, D.D. Hebrink et al. // J. Neuroimmunol. 2000. — Vol. 106, N 1−2. — P. 220−227.
- Astrocytes in chronic active multiple sclerosis plaques express MHC class II molecules / E. Zeinstra, N. Wilczak, C. Streefland, J. de Keyser // Neuroreport. -2000.-Vol. 11.-P. 89−91.
- Autoreactive CD8+ T cell responses to human myelin protein-delivered peptides / T. Tsuchida, K.C. Parker, R.V. Turner et al. // Proceedings of the National Academy of Sciences of the United States of America. 1994. — Vol. 91.-P. 10.859−10.863.
- Axonal changes in chronic demyelinated cervical spinal cord plaques / G. Lovas, N. Szilagyi, K. Majtenyi et al. // Brain. 2000. — Vol. 123. — P. 308−317.
- Axonal damage in acute multiple sclerosis lesions / B. Ferguson, M.K. Matyszak, M.M. Esiri et al. //Brain. 1997. — Vol. 120. — P. 393−399.
- Axonal transection in the lesions of multiple sclerosis / B.D. Trapp, J. Peterson, R.M. Ransohoff et al. // N. Engl. J. Med. 1998. — Vol. 338, N 5. — P. 278−285.
- Banking human neurospecimens / W.W. Tourtellotte, R.M. Nagra, R. Atkinson et al. // Encyclopedia of Neuroscience / eds. G. Adleman, B.H. Smith. 3rd revised edition. — Elsevier Science, 2004. — 1 CD-ROM.
- Barkhof, F. Can MRI be a predictor of long-term clinical outcome for MS? / F. Barkhof, M. Filippi // International Multiple Sclerosis Journal. 1995. — Vol. 2, Nl.-P. 4−9.
- BDNF and gpl45trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? / C. Stadelmann, M. Kerschensteiner, T. Misgeld, W. Bruck // Brain. 2000. — Vol. 125. — P. 75−85.
- Ben-Nun, A. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis / A. Ben-Nun, H. Wekerle, I.R. Cohen // Eur. J. Immunol. 1981. — Vol. 11. — P. 195−199.
- Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability / A. Falini, G. Calabrese, M. Filippi et al. // Am. I. Neuroradiology. 1998. — Vol. 19, N 2. — P. 223−229.
- Bhakdi, S. Complement lysis: a hole is a hole / S. Bhakdi, I. Tranum-Jensen // Immunol. Today. 1991. — Vol. 12. — P. 318−320.
- Biological properties of recombinant monocyte-derived interleukin 1 receptor antagonist / W.P. Arend, H.G. Welgus, R.C. Thompson, S.P. Eisenberg // J. Clin. Invest. 1990. — Vol. 85. — P. 1694−1697.
- Bjartmar, C. Axonal degeneration and progressive neurologic disability in multiple sclerosis / C. Bjartmar, B.D. Trapp // Neurotox. Res. 2003. — Vol. 5, N1−2.-P. 157−164.
- Bradbury, M.W.B. The blood-brain barrier: transport across the cerebral endothelium / M.W.B. Bradbury // Circ. Res. 1985. — Vol. 57. — P. 213−222.
- Brain and spinal cord MR in benign multiple sclerosis: a follow-up study / M. Filippi, A. Campi, V. Martinelli et al. // J. Neurol. Sci. 1996. — Vol. 143, N 1−2.-P. 143−149.
- Bright, J.J. Differential influence of interleukin-12 in the pathogenesis of autoimmune and virus-induced central nervous system demyelination / J.J. Bright, M. Rjdriguez, S. Sriram // J. Virol. 1999. — Vol. 73, N 2. — P. 16 371 639.
- Calabresi, P.A. Cytokines and other inflammatory mediators of axonal injury / P.A. Calabresi // Adv. Stud. Med. 2004. — Vol. 4, N 4B. — P. 322-S326.
- Cannella, В. The adhesion molecule and cytokine profile of multiple sclerosis lesions / B. Cannella, C.S. Raine // Ann. Neurology. 1995. — Vol. 37. — P. 424 435.
- CC chemokine receptor 5 polymorphism in rheumatoid arthritis / P. Garred, H. Madsen, J. Petersen et al. // J. Rheumatol. 1998. — Vol. 25, N 8. — P. 14 621 465.
- CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group / L.F. Barcellos, A.M. Schito, J.B. Rimmler et al. // Imunogenetics. 2000. — Vol. 51, N 4−5. — P.281−288.
- CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis / F. Sellebjerg, H.O. Madsen, C.V. Jensen et al. // J. Neuroimmunol. -2000. Vol. 102, N 1. — P. 98−106.
- Cellular immune reactivity within the CNS / H. Wekerle, C. Linington, H. Lassmann, R. Meyermann // Trends Neurol. Sci. 1986. — Vol. 9. — P. 271−277.
- Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis / A.R. Glabinski, M. Tani, V.K. Tuohy et al. // Brain Behav. Immun. 1995. — Vol. 9. — P. 315−330.
- Changes of P-amiloid precursor protein after compression trauma to the spinal cord: an experimental study in the rat using immunohistochemistry / G.L. Li, M. Farooque, A. Holtz, Y. Olsson // J. Neurotrauma. 1995. — Vol. 12. — P. 269−277.
- Characterization of MRI response to treatment with interferon beta-lb: contrast-enhancing MRI lesion frequency as a primary outcome measure / L.A. Stone, J.A. Frank, P. S. Albert et al. // Neurology. 1997. — Vol. 49. — P. 862 869.
- Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system (CNS) / C. Trebst, S.M. Staugaitis, B. Tucky et al. // Neuropathol. Appl. Neurobiol. 2003. — Vol. 29, N 6. — P. 584−595.
- Chemokines: function, regulation and alteration of inflammatory responses / N.W. Lukacs, C. Hogaboam, E. Campbell, S.L. Kunkel // Chem. Immunol. -1999.-Vol. 72.-P. 102−120.
- Circulating NK cell levels correlate with multiple sclerosis disease activity during pregnancy and in the postpartum period / L. Airas, M. Saraste, S. Vaisanen, A. Alanen // Mult, scler. 2005. — Vol. 11, N 1. — P. 122.
- Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study / S.J. Pittock, R.L. McClelland, W.T. Mayr et al. // Ann. Neurol. 2004. — Vol. 56, N 2. — P. 303−306.
- Clinical practice guideline process manual / eds. W. Edlund, G. Gronseth, Y. So, G. Franklin. American Academy of Neurology, 2004. — 44 p.
- Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor / U. Gubler, A.O. Chua, D.S. Schoenhaut et al. // Proc. Nat. Acad. Sci. 1991. — Vol. 88. — P. 4143−4147.
- Comi, G. Glatiramer acetate / G. Comi, L. Moiola // Neurologia. 2002. -Vol. 17, N5.-P. 244−258.
- Compston, A. Multiple sclerosis / A. Compston, A.J. Coles // Lancet. 2002. -Vol.359. — P. 1221−1231.
- Confavreux, C. Course and prognosis of multiple sclerosis assessed by the computerised data processing of 349 patients / C. Confavreux, G. Aimard, M. Devic//Brain. 1980.-Vol. 103.-P. 281−300.
- Confavreux, C. Early clinical predictors and progression of irreversible disability / C. Confavreux, S. Vukusic, P. Adeleine // Brain. 2003. — Vol. 126. — P. 770−782.
- Contribution of the interleukin-l (3 polymorphism in multiple system atrophy / M. Nishimura, H. Kawakami, O. Komure et al. // Mov. Disord. 2002. — Vol. 17.-P. 808−811.
- Corticosteroids do not prevent optic nerve atrophy following optic neuritis / S.J. Hickman, R. Kapoor, S.J. Jones et al. // J. Neurol. Neurosurg. Psychiatry. -2003.-Vol. 74.-P. 1139−1141.
- Course and prognosis in early-onset MS -Comparison with adult-onset forms / I.L. Simone, D. Carrara, C. Tortorella et al. // Neurology. 2002. — Vol. 59. -P. 1922−1928.
- Cross, А.Н. B-cells and antibodies in CNS demyelinating disease / A.H. Cross, J.L. Trotter, J.A. Lyons // J. Neuroimmunology. 2001. — Vol. 112. — P. 1−14.
- Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species / C.F. Brosnan, B. Cannella, L. Battistini et al. //Neurology. 1995. — Vol. 45. — S. 16-S21.
- Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients / K. Iamamura, A. Suzumura, F. Hayashi et al. // Acta Neurol. Scand. 1993. — Vol. 87. — P. 281−285.
- Dalakas, M.C. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects / M.C. Dalakas // Ann. Neurol. 1995. — Vol. 37, Suppl. 1. — S. 2−13.
- Davidson, A. Autoimmune diseases / A. Davidson, B. Diamond // N. Engl. J. Med. 2001. — Vol. 345, N 5. — P. 340−350.
- Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV / H. Bruhl, J. Cihak, M. Stangassinger et al. // J. Immunol. -2001. Vol. 166. — P. 2420−2426.
- Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment / M.D. Carrithers, I. Visintin, S.J. Kang, C.A. Janeway // Brain. 2000. — Vol. 123. — P. 1092−1101.
- Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (This) and Th2s / R. Bonecchi, G. Bianchi, P.P. Bordignon et al. // J. Exp. Med. 1998. — Vol. 187. — P. 129−134.
- Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes / Т.О. Jalonen, K. Pulkkinen, M. Ukkonen et al. // J. Neurol. 2002. — Vol. 249, N 5. — P. 576−583.
- Differential recognition of peptide analogs by naive verses activated PLP 139−151-specific CD4+ T cells / B.L. McRae, K.M. Nikcevich, WJ. Karpus et al. // J. Neuroimmunol. 1995. — Vol. 60, N 1−2. — P. 17−28.
- Dighiero, G. Critical self-epitopes are key to understanding of self-tolerance and autoimmunity / G. Dighiero, N.R. Rose // Immunol. Today. 1999. — Vol. 20. — P. 423−428.
- Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E) / K. Schreiber, A.B. Otura, L.P. Ryder et al. // Mult. Scler. -2002. Vol. 8, N 4. — P. 295−298.
- Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis / C.F. Lucchinetti, W. Bruck, M. Rodriguez, H. Lassmann // Brain pathology. 1996. — Vol. 6, N 3. — P. 259−274.
- Distribution of CCR5-delta 32 gene deletion across the Russian part of Eurasia / N.S. Yudin, S.V. Vinogradov, T.A. Potapova et al. // Hum Genet. -1998.-Vol. 102.-P. 695−698.
- Distribution of A32 alelle of the CCR5 gene in population of Poland / P.P. Jagodzinski, R. Lecybyl, M. Ignacak et al. // J. Med. Genet. 2000. — Vol. 45. -P. 271−274.
- Does Living on a Farm during Childhood Protect against Asthma, Allergic Rhinitis, and Atopy in Adulthood? / B. Leynaert, C. Nuekirch, D. Jarvis et al. // Am. J. Respir. Crit. Care Med. 2001. — Vol. 164, N 10. — P. 1829−1834.
- Early onset multiple sclerosis a longitudinal study / A. Boiko, G. Vorobeychik, V. Devonshire et al. // Neurology. 2002. — Vol. 59. — P. 10 061 010.
- Ebers, G.C. Natural history of multiple sclerosis / G.C. Ebers // J. Neurol. Neurosurg. Psychiatry. 2001. — Vol. 71. — P. 16−19.
- Ebers, G.C. Natural history of primary progressive multiple sclerosis / G.C. Ebers //Multiple Sclerosis. 2004. — Vol. 10. — S8-S15.
- Ebers, G.C. The geography of MS reflects genetic susceptibility / G.C. Ebers, D. Bulman // Neurology. 1986. — Vol. 36. — P. 108.
- Effect of early interferon treatment on conversion to definite multiple sclerosis / G. Comi, M. Filippi, F. Barkhof et al. // Lancet. 2001. — Vol. 357. -P. 1576−1582.
- Esiri, M.M. Immunoglobuli-containing cells in multiple sclerosis plaques M.M. Esiri // Lancet. 1977. — Vol. 2. — P. 478.
- Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients / T.L. Sorensen, M. Tani, J. Jensen et al. //J. Clin. Invest. 1999. — Vol. 103, N 6. — P. 807−815.
- Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-lb and IL-1 receptor antagonist / J.S.H. Liu, M.-L. Zhao, C.F. Brosnan, S.C. Lee // J. Immunol. 1996. — Vol. 157. — P. 3569.
- Extended use of glatiramer acetate (Copaxone) is well-tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability / K.P. Johnson, B.P. Brooks, J.A. Cohen et al. // Neurology. 1998. -Vol. 50.-P. 708−710.
- Factors that influence adherence with disease-modifying therapy in multiple sclerosis / K. Treadaway, K. Hwaker, M. Racke et al. // Mult, scler. 2005. -Vol. 11, N l.-P. 158.
- Fazakerley, J.K. Pathogenesis of virus-induced demyelination / J.K. Fazakerley, M.J. Buchmeier // Adv. Virus. Res. 1993. — Vol. 42. — P. 249−324.
- Filippi, M. The role of new magnetic resonance techniques in the evaluation of multiple sclerosis / M. Filippi // International Multiple Sclerosis Journal. -1998.-Vol. 4, N 3. P. 89−102.
- Galetta, S.L. Immunomodulatory agents for the treatment of relapsing multiple sclerosis / S.L. Galetta, C. Markowitz, A.G. Lee // Archives of Internal Medicine. 2002. — Vol. 162. — P. 2161−2169.
- Garcia-Gallego, A. Prevalence and characteristics of multiple sclerosis in the health district of the Marina Alta / A. Garcia-Gallego, J. Morera-Guitart // Rev. Neurol. 2002. — Vol. 34, N 8. — P. 732−737.
- Genetic polymorphism of IL-12 p40 gene in immune-mediated disease / M.A. Hall, E. McGlinn, G. Coakley et al. // Genes Immun. 2000. — Vol. 1, N 3.-P. 219−224.
- Genetic polymorphisms of IL-lbeta and IL-1 receptor antagonist in association with multiple sclerosis in Japanese patients / M. Niino, S. Kikuchi, T. Fukazawa et al. // J. Neuroimmunol. 2001. — Vol. 118, N 2. — P. 295−299.
- Genetic restriction HTV-1 infection and progression to AIDS by a deletion allele CKR5 structural gene / M. Dean, M. Carrington, C. Winkler et al. // Science. 1996.-Vol. 283.-P. 1856- 1862.
- Glabinski A.R., Ransohoff R.M. Roles of Chemokines and Their Receptors in Neuroinflammation / A.R. Glabinski, R.M. Ransohoff // Neuroinflammation: Mechanisms and Management / ed. P.L. Wood. Humana Press Inc., Totowa, NJ, 2003.-P. 99−115.
- Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis / P.W. Duda, M.C. Schmied, S.L. Cook et al. //J. Clin. Inves. 2000. — Vol. 105. — P. 967−976.
- Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy / T. Ziemssen, T. Kumpfel, W.E.F. Klinkert et al. // Brain. 2002. — Vol. 125. — P. 2381−2391.
- Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ /R. Aharoni, B. Kayhan,
- R. Eilam et al. // Proc. Natl. Acad. Sci. USA. 2003. — Vol. 100, N 24. — P. 14 157−14 162.
- Glezer, I. Glucocorticoids: protectors of the brain during innate immune responses / I. Glezer, S. Rivest // Neuroscientist. 2004. — Vol. 10, N 6. — P. 538−552.
- Global distribution of the CCR5 gene 32-basepair deletion / J.J. Martinson, N.H. Chapman, D.C. Rees et al. //Nature genetics. 1997. — Vol. 16. — P. 100 103.
- Global distribution of the CCR5 genotype and CCR-5 gene defects in HIV-1 transmission and disease progression / J.J. Martinson, N.H. Chapman, D.C. Rees et al. //Nat. Med. 1997. — Vol. 3. — P. 338−340.
- Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring treatment of multiple sclerosis / M. Filippi, M.A. Horsfield, H.J. Ader et al. // Ann. Neurol. 1998. — Vol. 43. — P. 499−506.
- Guseo, A. The significance of perivascular infiltrates in multiple sclerosis /
- A. Guseo, K. Jellinger // J. Neurology. 1975. — Vol. 211. — P. 51−60.
- Hafler, D.A. T-cell in multiple sclerosis and inflammatory central nervous system diseases / D.A. Hafler, H.L. Weiner // Immunol. Rev. 1987. — Vol. 100. -P. 307−332.
- Hartung, H.P. Experimental autoimmune encephalomyelitis / H.P. Hartung,
- B.C. Kieseier // Neuroinflammation: Mechanisms and Management / ed. P.L. Wood. -, 2nd ed. Humana Press Inc., Totowa, NJ, 2003. — P. 345−357.
- Hartung, H.P. Pathogenesis of multiple sclerosis / H.P. Hartung // Frontiers in multiple sclerosis / eds. O. Abramsky, H. Ovada. Martin Dunitz, 1997. — P. 45−59.
- Hawkins, S.A. Benign multiple sclerosis? Clinical course, long term follow up, and assesment of prognostic factors / S.A. Hawkins, G.V. McDonnell // J. Neurol. Neurosurg. Psychiatry. 1999. — Vol. 67. — P. 148−152.
- Hohlfeld, R. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines / R. Hohlfeld, H. Wekerle // PNAS. 2004. — Vol. 10, suppl. 2. — P. 14 599−14 606.
- Hohlfeld, R. Basic principles of immunotherapy for neurological diseases / R. Hohlfeld, M.C. Dalakas // Semin. Neurol. 2003. — Vol. 23, N 2. — P. 121 132.
- Hohlfeld, R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives / R. Hohlfeld // Brain. 1997. -Vol. 120. — P. 865−916.
- Hohlfeld, R. Immunologic factors in primary progressive multiple sclerosis / R. Hohlfeld // Mult, scler. 2004. — Vol. 10. — P. 16−22.
- Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection / R. Liu, W.A. Paxton, S. Choe et al. // Cell. 1996. — Vol. 86. — P. 367−377.
- Horikawa, Y. Rubella antibody in multiple sclerosis / Y. Horikawa, T. Tsubaki, M. Nakajima // Lancet. 1973. — Vol. 1. — P. 996−997.
- Humoral autoimmunity as a mediator of CNS repair / A.J. Bieber, A. Warrington, L.R. Pease, M. Rodriguez // Trends Neurosci. 2001. — Vol. 24, suppl. 11.-P. 39−44.
- Hurme, M. IL-1 receptor antagonist (IL-IRa) plasma levels are co-ordinately regulated by both IL-IRa and IL-lbeta genes / M. Hurme, S. Santtila // Eur. J. Immunol. 1998. — Vol. 28. — P. 2598−2602.
- Imaging axonal damage of normal-appearing white matter in multiple sclerosis / L. Fu, P.M. Matthews, N. de Stefano et al. // Brain. 1998. — Vol. 121.-P. 103−113.
- Imaging promary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques / M. Filippi, M. Rovaris, M.A. Rocca et al. // Mult. Scler. 2004. — Vol. 10. — P. 36−45.
- Immune system genes in multiple sclerosis: genetic association and linkage analyses on TCR beta, IGH, IFN-gamma and IL-lra/IL-1 beta loci / K. Wansen, T. Pastinen, S. Kuokkanen et al. // J. Neuroimmunol. 1997. — Vol. 79, N 1. — P. 29−36.
- Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules / I. Duran, E.M. Martinez-Caceres, J. Rio et al. // Brain. 1999. — Vol. 122. — P. 2297−2307.
- Immunopathology of multiple sclerosis: report on an international meeting held at the institute of Neurology of the Univeristy of Vienna / H. Lassmann, C.S. Raine, J. Antel, J.W. Prineas // J. Neuroimmunology. 1998. — Vol. 86, N 2.-P. 213−217.
- Immunopathology of secondary-progressive multiple sclerosis / J.W. Prineas, E.E. Kwon, E.S. Cho et al. // Ann. Neurology. 2001. — Vol. 50. — P. 646−657.
- In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3 and CCR5 / L. Zhang, T. He, A. Talal et al. // J. Virol. 1998. — Vol. 72. — P. 5035 — 5045.
- Incidence and significance of neutralizing antibodies to interferon beta-la in multiple sclerosis / R.A. Rudick, N.A. Simonian, J.A. Alam et al. // Neurology. 1998.-Vol. 50.-P. 1266−1272.
- Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis / K. Pulkkinen, M. Luomala, H. Kuusisto et al. // Acta Neurol. Scand. 2004. — Vol. 109, N5.-P. 342−347.
- Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis / J. Beck, P. Rondot, L. Catinot et al. // Acta Neurol. Scand. 1988. — Vol. 78. — P. 318−323.
- Inflammation in multiple sclerosis: the good, the bad, and the complex / G. Martino, L. Adorini, P. Rieckmann et al. // Lancet Neurology. 2002. — Vol. 1. -P. 499−509.
- Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course / J.A. Silversides, S.V. Heggarty, G.V. McDonnell et al. // Mult. Scler. 2004. — Vol. 10, N 2. — P. 149−152.
- Interactions between oligodendrocytes and micriglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing / J.P. Zajicek, M. Wing, N.J. Scolding, D.A. Compston // Brain. 1992. -Vol. 115.-P. 1611−1631.
- Interferon beta in the treatment of multiple sclerosis: mechanisms of action / V.W. Yong, S. Chabot, O. Stuve, G. Williams // Neurology. 1998. — Vol. 51. -P. 682−689.
- Interferon beta-lb in the treatment of multiple sclerosis: final outcome of the randomized controlled trial / The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group // Neurology. 1995. -Vol. 45.-P. 1277−1285.
- Interferon in relapsing-remitting multiple sclerosis / G.P.A. Rice, B. Incorvaia, L. Munari et al. // The Cochrane Database of Systematic Reviews. -2006. Is. 2.-10.1002/14 651 858.CD002002.
- Interleukin (IL)-l gene polymorphisms: relevance of disease severity assocoated alleles with IL-lbeta and IL-lra production in multiple sclerosis / H.M. Schrijver, J. van As, J.B. Crusius et al. // Mediators Inflamm. 2003. -Vol. 12, N2.-P. 89−94.
- Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity / C.L.A. Mann, M.B. Davies, V.L. Stevenson et al. // J. Neuroimmunol. 2002. — Vol. 129, N 1. — P. 197−204.
- Interleukin-12 p40 polymorphism and susceptibility to multiple sclerosis / I. Alloza, S. Heggarty, A. Goris et al. // Ann. Neurol. 2002. — Vol. 52. — P. 524 525,
- Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis / T. van Veen, J.B. Crusius, H.M. Schrijver et al. // Ann. Neurol. -2001.-Vol. 50, N2.-P. 275.
- Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) / L.D. Jacobs, D.L. Cookfair, R.A. Rudick et al. // Ann. Neurol. -1996.-Vol. 39.-P. 285−294.
- Intrathecal synthesis of free immunoglobulin light chains and IgM in initial multiple sclerosis / F. Lolli, G. Siracusa, M.P. Amato et al. // Acta Neurol. Scand. 1991. — Vol. 83. — P. 239−243.
- Jacobson, S. Association of human herpesvirus-6 and multiple sclerosis: here we go again? / S. Jacobson // J. Neurovirol. 1998. — Vol. 4, N 5. — P. 471 473.
- Johnson, H.M. Superantigens: structure and relevance to human disease / H.M. Johnson, B.A. Torres, J.M. Soos // Proc. Soc. Exp. Biol. Med. 1996. -Vol. 212, N2.-P. 99−109.
- Kantor, R A mutated CCR5 gene may have favorable prognostic implications in MS / R. Kantor, M. Bakhanashvili, A. Achiron // Neurology. -2003. Vol. 61, N 2. — P. 238−240.
- Karpus, W.J. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis / W.J. Karpus, R.M. Ransohoff // J. Immunol. 1998. — Vol. 161. -P. 2667−2671.
- Kastrup, O. Balo’s concentric sclerosis. Evolution of active demyelination demonstrated by serial contrastenhanced MRI / O. Kastrup, P. Stude, V. Limmroth // J. Neurol. 2002. — Vol. 249, N 7. — P. 811−814.
- Keyser, J. de Are astrocytes central players in the pathophysiology of multiple sclerosis? / J. de Keyser, E. Zeinstra, E. Frohman // Arch. Neurol. -2003.-Vol. 60.-P. 132−136.
- Kleinschmidt-DeMasters, B.K. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-la for multiple sclerosis / B.K. Kleinschmidt-DeMasters, K.L. Tyler // N. Engl. J. Med. 2005. -Vol. 353.-P. 369−374.
- Kurtzke, J.F. Epidemiology of multiple sclerosis in US veterans. Part I. Race, sex and geographic distribution / J.F. Kurtzke, J.W. Beebe, J.E. Norman //Neurology. 1979. — Vol. 29. — P. 1228−1235.
- Kurtzke, J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) / J.F. Kurtzke // Neurology. 1983. -Vol. 33.-P. 1444−1452.
- Lack of association between IL-1 A and IL-1B promoter polymorphisms and multiple sclerosis / C. Ferri, F.L. Sciacca, L.M.E. Grimaldi et al. // J. Neurol. Neurosurg. Psychiaty. 2000. — Vol. 69. — P. 564−565.
- Lalani, A.S. Modulating chemokines: more lessons from viruses / A.S. Lalani, J.W. Barrett, G. McFadden // Immunol. Today. 2000. — Vol. 21. — P. 100−106.
- Lassmann, H. Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis / H. Lassmann. — Berlin: Springer-Verlag, 1983. -P.l-135.
- Late complications of immune deviation therapy in a nonhuman primate / G.P. Genain, K. Abel, N. Belmar et al. // Science. 1996. — Vol. 274. — P. 20 542 057.
- Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice / D.R. Koh, W.P. Fung-Leung, A. Ho et al. // Science. 1992. -Vol. 256.-P. 1210−1213.
- Lieberman, J. The ABCs of granule-vediated cytotoxicity: new weapons in the arsenal / J. Lieberman // Nat. Rev. Immunol. 2002. — Vol. 13. — P. 361−370.
- Link, H. The cytokine storm in multiple sclerosis / H. Link // Mult. Scler. -1998.-Vol. 4, N 1. P. 12−15.
- Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele / G. Morahan, D. Huang, S.I. Ymer et al. // Nat. Genet. -2001.-Vol. 27.-P. 218−221.
- Lobinska, A. Epidemiological aspects of multiple sclerosis in Lublin (Poland) / A. Lobinska, Z. Stelmasiak // Neurol. Neurochir. Pol. 2004. — Vol. 38, N5.-P. 361−366.
- Long-term adherence to first disease-modifying drug and reasons for discontinuation in 194 patients with relapsing-remitting multiple sclerosis / A. Jacob, S. Rashid, J. Ramtahal et al. // Mult. Scler. 2005. — Vol. 11, N 1. — P. 157.
- Long-term MRI observations of childhood-onset relapsing-remitting multiple sclerosis / C. Balassy, G. Bernert, C. Wober-Bingol et al. // Neuropediatrics. 2001. — Vol. 32, N 1. — P. 28−37.
- Lublin, F.D. Defining the clinical course of multipe sclerosis: results of an international survey / F.D. Lublin, S.C. Reigold // Neurology. 1996. — Vol. 46. -P. 907−911.
- Lublin, F.D. Effect of relapses on development of residual deficit in multiple sclerosis / F.D. Lublin, M. Baier, G. Cutter // Neurology. 2003. — Vol. 61, N 11.-P. 1528−1532.
- Lucchinetti, C.F. Neuroimmunologic mechanisms in the etiology of multiple sclerosis / C.F. Lucchinetti, W. Bruk, H. Lassmann // Neuroinflammation: Mechanisms and Management / ed. P.L. Wood. Humana Press Inc., Totowa, NJ, 2003.-P. 359−377.
- Maeda, A. Matrix metallopreteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions / A. Maeda, R.A. Sobel //J. Neuropathol. Exp. Neurol. 1996. — Vol. 55. — P. 300−309.
- Major differences in the dynamics of primary and secondary multiple sclerosis / A.J. Thompson, A.G. Kermode, D. Wicks et al. // Ann. Neurology. -1991.-Vol. 29.-P. 53−62.
- Management of multiple sclerosis / R.R. Rudick, A.J. Cohen, A. Jeffrey et. al. // N. Engl. J. Med. 1997. — Vol. 337, N 22. — P. 1604−1611.
- Martino, G. How the brain repairs itself: new therapeutic strategies in inflammatory and degenerative CNS disorders / G. Martino // Lancet Neurology. 2004. — Vol. 3. — P. 372−378.
- Matrix metalloproteinases and diseases of the CNS / V.W. Yong, C.A. Krekoski, P.A. Forsyth et al. // Trends Neurosci. 1998. — Vol. 21. — P. 75−80.
- Matrix metalloproteinases, tumour necrosis factor and multiple sclerosis: An overview / S. Chandler, K.M. Mille, J.M. Clements et al. // J. Neuroimmunol. -1997.-Vol. 72.-P. 155−161.
- McAlpine, D. The benign form of multiple sclerosis. A study based on 241 cases seen within 3 years of onset and followed until the tenth year or more of the disease / D. McAlpine // Brain. 1961. — Vol. 84. — P. 186−203.
- McDonnell, G.V. Multiple sclerosis in Northern Ireland: a historical and global perspective / G.V. McDonnell, S.A. Hawkins // Ulster. Med. J. 2000. -Vol. 69, N2.-P. 97−105.
- Medical progress: multiple sclerosis / J.H. Noseworthy, C.F. Lucchinetti, M. Rodriguez, B.G. Weinshekner // N. Engl. J. Med. 2000. — Vol. 343. — P. 938 952.
- Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway / R. Diem, M. Hobom, K. Maier et al. // J. Neurosci. 2003. — Vol. 23, N 18. — P. 6993−7000.
- Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-lb therapy / J.H. Uhm, N.P. Dooley, O. Stuve et al. // Ann. Neurol. 1999. — Vol. 46. — P. 319−324.
- Minderhoud, J.M. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study / J.M. Minderhoud, J.H. van der Hoeven, A.J. Prange // Acta Neurol. Scand. 1988. — Vol. 78. — P. 10−15.
- Molecular cloning and functional expression of a new human CC-chemokine receptor gene / M. Samson, O. Labbe, C. Mollereau et al. // Biochemostry. -1996. Vol. 35. — P. 3362 — 3367.
- Multiple actions of steroid hormones: a focus on rapid, nongenomic effects / E. Falkenstein, H.C. Tillmann, M. Christ et al. // Pharmacol. Rev. 2000. — Vol. 52.-P. 513−556.
- Multiple sclerosis in childhood: Clinical features of 149 cases. / A. Ghezzi, V. Deplano, J. Faroni et al // Multiple Sclerosis. 1997. — Vol. 3. — P. 4316.
- Multiple sclerosis- in situ evidence for antobody and complement mediated demyelination / M.K. Storch, S. Piddlesden, M. Haltia et al. // Ann. Neurol. -1998.-Vol. 43.-P. 465−471.
- Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein / R.-B. Lindert, C.G. Haase, U. Brehm et al. // Brain. 1999. — Vol. 122. — P. 2089−2099.
- Multiple sclerosis: cytokine profiles on peripheral blood mononuclear cells / O. Fernandez, L. Leyva, G. Luque et al. // Mult, scler. 2001. — Vol. 7, N 1. — P. 35.
- Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment / H. Wiendl, O. Neuhaus, L. Kappos, R. Hohlfeld // Nervenarzt. 2000. — Vol. 71, N 8. — P. 597−610.
- Murray, T.J. Infection as a cause of multiple sclerosis. Theories abound because no one knows the answer yet / T.J. Murray // BMJ. 2002. — Vol. 325. -P. 1128.
- Myelin antigen reactive T cells in cerebrovascular diseases / W.Z. Wang, T. Olsson, V. Kostulas et al. // Clin. Exp. Immunol. 1992. — Vol. 88. — P. 157 162.
- Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice / D. Sun, J.N. Whitaker, Z. Huang et al. // J. Immunol. 2001. — Vol. 166, N 12. — P. 7579−7587.
- Nakashima, I. Magnetic resonance imaging for the diagnosis of multiple sclerosis / I. Nakashima, K. Fujihara, Y. Itoyama // Nippon Rinsho. 2003. -Vol. 61, N8.-P. 1340−1346.
- Natural killer type 2 bias in remission of multiple sclerosis / K. Takahashi, S. Miyake, T. Kondo et al. // J. Clin. Invest. 2001. — Vol. 107. — P. R23-R29.
- Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients / C. Bjartmar, G. Kidd, S. Mork et al. // Ann. Neurology. 2000. — Vol. 48, N 6. — P. 893−901.
- NK cell phenotypes in MS: CDllc versus CD95 expression in remission state of MS / T. Aranami, S. Miyake, T. Yamamura // Mult, scler. 2005. — Vol. 11, N 1. — P. 122.
- Nomenclature for chemokine receptors / P.M. Murphy, M. Baggiolini, I.F. Charo et al. // Pharmacol, reviews. -2001. Vol. 52, N 1. — P. 1245−1273.
- Noort, J.M. van Multiple sclerosis: an altered immune response or an altered stress response? / J.M. van Noort // J. Mol. Med. 1996. — Vol. 74, N 6. — P. 285−296.
- Noseworthy, J.H. Progress in determinating the causes and treatment of multiple sclerosis / J.H. Noseworthy // Nature. 1999. — Vol. 399, suppl. 6738. -P. 40−47.
- Oligodendrocyte susceptibility to injury by T-cell perforin / N. Scolding, J. Jones, D.A. Compston, B.P. Morgan // Immunology. 1990. — Vol. 70. — P. 610.
- Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis / K. Banki, E. Colombo, F. Sia et al. // J. Exp. Med. 1994. -Vol. 180, N5.-P. 1649−1663.
- Patterns of disease activity in multiple sclerosis: a clinical and magnetic resonance imaging study / A.J. Thompson, A.G. Kermode, D.G. MacManus et al. // BMJ. 1990. — Vol. 300. — P. 631−634.
- Perivascular T cells express the proinflammatory chemokine RANTES mRNA in multiple sclerosis lesions / J. Hvas, C. McLean, J. Justesen et al. // Scand. J. Immunol. 1997. — Vol. 46. — P. 195−203.
- Pette, E. Viriligische Aspekte bei der multiplen Sklerose / E. Pette, H. Pette. // Dtsch. Z. Nervenheilk. 1963. — Bd. 185. — S. 295−307.
- Plaque-associated expression of human herpesvirus 6 in multiple sclerosis / P.B. Challoner, K.T. Smith, J.D. Parker et al. // Proc. Natl. Acad. Sci. USA. -1995. Vol. 92. — P. 7440−7444.
- Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination / M. Rodriguez, W.E. Karnes, J.D. Bartleson, A.A. Pineda // Neurology. 1993. — Vol. 43. — P. 1100−1104.
- Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat / J.K. Tarlow, A.I.F. Blakemore, A. Lennard et al. // Hum. Genet. 1993. — Vol. 91. — P. 403−404.
- Polymorphisms in the IL-12B gene and outcome of HCV infection / A. Houldsworth, M. Metzner, S. Rossol et al. // J. Interferon Cytokine Res. 2005. -Vol. 25, N5.-P. 271−276.
- Premack, B.A. Chemokine receptors: gateways to inflammation and infection / B.A. Premack, T.J. Schall // Nat. Med. 1996. — Vol. 2. — P. 11 741 178.
- Preservation of motor function by inhibition of CD8(+) virus peptide-specific T cells in Theiler’s virus infection / A.J. Johnson, J. Upshaw, K.P. Pavelko et al. // FASEB J. 2001. — Vol. 15. — P. 2760−2762.
- Primary progressive multiple sclerosis / A.J. Thompson, C.H. Polman, D.H. Miller, W.I. McDonald et al. // Brain. 1997. — Vol. 120. — P. 1085−1096.
- Prineas, J.W. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown / J.W. Prineas, J.S. Graham // Ann. Neurol. 1981.-Vol. 10.-P. 308−317.
- PRISMS-4: Long-term efficacy of interferon-p-la in relapsing MS / The PRISMS (Prevention of Relapses and Disability by Interferon-b-la Subcutaneously in Multiple Sclerosis) Study Group- the University of British
- Columbia MS/MRI Analysis Group // Neurology. 2001. -Vol. 56. — P. 16 281 636.
- Progressive cerebral atrophy in multiple sclerosis. A serial study / N.A. Losseff, L. Wang, H.M. Lai et al. // Brain. 1996. — Vol. 119. — P. 2009−2019.
- Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein / D.B. Carter, M.R. Deibel, C.J. Dunn et al. //Nature. 1990. — Vol. 344. — P. 633−638.
- Qin, Y. B-cell immunity in MS / Y. Qin, P. Duquette // International MS Journal. 2003. — Vol. 10. — P. 110−120.
- Quiros, E. Superantigenos: concepto у aplicaciones en la patogenia у tratamiento de enfermedades infecciosas у autoinmunes / E. Quiros, M.C. Maroto // An. Med. Interna. 1996. — Vol. 13, N 7. — P. 347−352.
- Raine, C.S. The Dale E. McFarlin Memorial Lecture: The immunology of the multiple sclerosis lesion / C.S. Raine // Ann. Neurol. 1994. — Vol. 36. — P. 61−72.
- Randomized double-blind placebocontrolled study of interferon-la in relapsing/remitting multiple sclerosis. PRISMS study group. // Lancet. 1998. -Vol. 352. — P. 1498−1504.
- Randomized, comparative study of interferon beta-la treatment regimens in MS: the EVIDENCE trial / H. Panitch, D.S. Goodin, G. Francis et al. // Neurology. 2002. — Vol. 59. — P. 1496−1506.
- Ransohoff, R.M. The Chemokine System in Neuroinflammation / R.M. Ransohoff// J. Infect. Dis. 2002. — Vol. 186, suppl. 2. — P. 152−156.
- Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis / W.I. Mc Donald, A. Compston A., G. Edan et al. // Ann. Neurol. 2000. — Vol. 5. — P. 121−127.
- Relapses and pregression of disability in multiple sclerosis / C. Confavreux, S. Vukusic, T. Moreau, P. Adeleine // N. Engl. J. Med. 2000. — Vol. 343. — P. 1430−1438.
- Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients / F.L. Sciacca, C. Ferri, K. Vandenbroeck et al. // Neurology. 1999. — Vol. 52. — P. 1896.
- Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene / C.M. Alexander, E.W. Howard, M.J. Bissel, Z. Werb // J. Cell. Biol. 1996. — Vol. 135. — P. 16 691 677.
- Rodriguez, M. Ultrastructure of multiple sclerosis / M. Rodriguez, B.W. Scheithauer// Ultrastruct. Pathol. 1994. — Vol. 18. — P. 3−13.
- Rossi, D. The biology of chemokines and their receptors / D. Rossi, A. Zlotnik // Ann. Rev. Immunol. 2000. — Vol. 18. — P. 217−242.
- Sadovnick, A.D. Epidemiology of multiple sclerosis: a critical overview / A.D. Sadovnick, G.C. Ebers // Can. J. Neurol. Sci. 1993. — Vol. 20, N 1. — P. 17−29.
- Sallusto, F. Chemokines and chemokine receptors in T-cell priming and Thl/Th2-mediated responses / F. Sallusto, A. Lanzavecchia, C.R. Mackay // Immunol. Today. 1998. — Vol. 19. — P. 568−574.
- Schwartz, M. Physiological approaches to neuroprotection, boosting of protective autoimmunity / M. Schwartz // Surv. Ophthalmol. 2001. — Vol. 45, N3.-P. 256−260.
- Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features / N. Tubridy, A.J. Coles, P. Molyneux et al. //Brain. 1998. — Vol. 121, Pt. 2. — P. 225−231.
- Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis / W.H. Stuart, S. Cohan, J.R. Richert, A. Achiron // Neurology. 2004. — Vol. 63, suppl. 5. — P. 19−27.
- Sensitivities and predictive values of paraclinical tests for diagnosing multiple sclerosis / G. Filippi, G.C. Comi, V. Cosi et al // Neurology. 1994. -Vol. 241.-P. 132−137.
- Sentries at the gate: chemokines and the blood-brain barrier / A.R. Glabinski, R.M. Ransohoff// J. Neurovirol. 1999. — Vol. 5. — P. 623−634.
- Serial gadolinium-enchanced MRI in patients with multiple sclerosis of varying levels of disability / M. Filippi, P. Rossi, M.A. Rocca et al // American journal of neuroradiology. 1997. — Vol. 18, N 8. — P. 1549−1556.
- Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study / M.A. Lee, J. Palace, G. Stabler et al. // Brain. 1999. — Vol. 122. — P. 191−197.
- Shaw, S.Y. Analogous amino acid sequences in myelin proteolipid and viral proteins / S.Y. Shaw, R.A. Laursen, M.B. Lees // FEBS Lett. 1986. — Vol. 207, N 2. — P. 266−270.
- Shevach, E.M. Regulatory N cells in autoimmunity / E.M. Shevach // Ann. Rev. Immunol. 2000. — Vol. 18. — P. 423−449.
- Silverstein, A.M. There is only one immune system! The view from immunopathology / A.M. Silverstein, N.R. Rose // Semin. Immunol. 2000. -Vol. 12, N 3. — P. 173−178, 257−344.
- Stadelmann, С. Lessons from the neuropathology of atypical forms of multiple sclerosis / C. Stadelmann, W. Bruck // Neurol. Sci. 2004. — Vol. 25, suppl. 4.-P. 319−322.
- Stinissen, P. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies / P. Stinissen, J. Raus, J. Zhang // Crit. Rev. Immunol. 1997. — Vol. 17, N 1. — P. 33−75.
- Subpial demyelination in the cerebral cortex of multiple sclerosis patients / L. Bo, C.A. Vedeler, H.I. Nyland et al. // J. Neuropathol. Exp. Neurol. 2003. -Vol. 62, N7.-P. 723−732.
- Superantigen reactivity of gamma delta T cell clones isolated from patients with multiple sclerosis and controls / P. Stinissen, C. Vandevyver, J. Raus, J. Zhang // Cell. Immunol. 1995. — Vol. 166, N 2. — P. 227−235.
- Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group / K.P. Johnson, B.R. Brooks, C.C. Ford et al. // Mult. Scler. 2000. -Vol. 6. — P. 255−266.
- Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States / C.G. Parks, G.S. Cooper, M.A. Dooley et al. // Ann. Rheum. Dis. 2004. — Vol. 63. — P. 9194.
- The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic / G. Ferlazzo, D. Thomas et al. // J. Immun. 2004. — Vol. 172. — P. 1455−1462.
- The blood-brain barrier in neuroinflammatory diseases / H.E. de Vries, J. Kuiper, A.G. de Boer et al. // Pharmacol. Reviews. 1997. — Vol. 2, N 2. — P. 143−155.
- The CCR deletion mutation fails to protect against multiple sclerosis / B.H. Bennetts, S.M. Teutsch, M.M. Buhler et al. // Hum. Immunol. 1997. — Vol. 58, Nl.-P. 52−59.
- The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians / O.O. Favorova, T.V. Andreewski, A.N. Boiko et al. // Neurology. 2002. — Vol. 59, N 10. — P. 1652−1655.
- The effect of human herpesvirus-6 (HHV-6) on cultured human neural cells: oligodendrocytes and microglia / A.V. Albright, E. Lavi, J.B. Black et al. // J. Neurovirol. 1998. — Vol. 4, N 5. — P. 486−494.
- The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2ql4-q21, in the region of the IL-1-alpha and IL-1-beta loci / A. Steinkasserer, N.K. Spurr, S. Cox et al. // Genomics. 1992. — Vol. 13. — P. 654−657.
- The Interleukin 1 Gene Cluster Contains a Major Susceptibility Locus for Ankylosing Spondylitis / A.E. Timms, A.M. Crane, A.M. Sims et al. // Am. J. Hum. Genet. 2004. — Vol. 75. — P. 587−595.
- The natural history of multiple sclerosis: a geographically based study / B.G. Weinshenker, B. Bass, G.P.A. Rice et al. // Brain. 1989. — Vol. 112. — P. 133 146.
- The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome / B.G. Weinshenker, G.P.A. Rice, J.H. Noseworthy et al. // Brain. 1991. — Vol. 114. -P. 1045−1056.
- The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation / M. Kremenchutzky, D. Cottrell, G. Rice et al. // Brain. 1999. -Vol. 122.-P. 1941−1949.
- The role of a mutant CCR5 allele in HIV-1 transmission and disease progression / Y. Huang, W.A. Paxton, S.M. Wolisky et al. // Nat. Med. 1996. -Vol. 2.-P. 1240−1243.
- Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: relationship to adherence to treatment / D.C. Mohr, D.E. Goodkin, W. Likosky et al. // Mult. Scler. 1996. — Vol. 2, N 5. — P. 222−226.
- Thompson, A. Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis / A. Thompson // Mult. Scler. 2004. — Vol. 10.-P. 2−7.
- Thompson, A.J. Benign multiple sclerosis / A.J. Thompson // J. Neurol. Neurosurg. Psychiatry. 1999. — Vol. 67. — P. 138.
- TNF alpha promotes proliferation of oligodendrocyte and remyelination / H.A. Arnett, J. Mason, M. Marino et al. // Nat. Neurosci. 2001. — Vol. 4. — P. 1116−1122.
- TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group // Neurology. 1999. -Vol. 53, N3.-P. 457−465.
- Tourtellotte, W.W. MS: Why virus? / W.W. Tourtellotte // Mult. Scler. Newsletter. 2004. — Vol. 3. — P. 5−12.
- Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression / S.E. Baranzini, C. Elfstrom, S.-Y. Chang et al. //J. Immunol. 2000. — Vol. 165. — P. 6576−6582.
- Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions / J.W. Peterson, L. Bo, S. Mork et al. // Ann. Neurol. -2001. Vol. 50, N 3. — P. 389−400.
- Trapp, B.D. Mechanisms of axonal loss and neuronal dysfunction in MS B.D. Trapp //Adv. Stud. Med. 2004. — Vol. 4, N 4B. — P. 312−315.
- Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system / H.S. Panitch, R.L. Hirsch, J. Schindler, K.P. Johnson //Neurology. 1987. — Vol. 37. — P. 1097−1102.
- Trebst, C. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges / C. Trebst, R.M. Ransohoff// Arch. Neurol. 2001. — Vol. 58. — P. 1975−1980.
- Tremlett, H.L. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS / H.L. Tremlett, J. Oger // Neurology. 2003. -Vol. 61, N4.-P. 551−554.
- Um, J.Y. Frequencies of interleukin 1 gene polymorphisms in Koreans / J.Y. Um, H.M. Kim // Clin. Chem. 2003. — Vol. 49, N 12. — P. 2101−2102.
- Waterer, G.W. Science review: Genetic variability in the systemic inflammatory response / G.W. Waterer, R.G. Wunderink // Critical Care. -2003. Vol. 7, N 4. — P. 308−314.
- Wegner, C. Pathological differences in acute inflammatory demyelinating diseases of the central nervous system / C. Wegner // Int. MS J. 2005. — Vol. 12.-P. 12−19.1. J sL-ул
- Werner, P. Glutamate exitotoxicity a mechnism for axonal damage and oligodendrocyte death in multiple sclerosis? / P. Werner, D. Pitt, C.S. Raine // Journal of neural transmission. — 2000. — Vol. 60, suppl. — P. 375−385.
- Wingerchuk, D.M. Multiple sclerosis: current pathophysiological concepts / D.M. Wingerchuk, C.F. Lucchinetti, J.H. Noseworthy // Lab. invest. 2001. -Vol. 81, N3.-P. 263−281.
- Wingerchuk, D.M. Neuromyelitis optica / D.M. Wingerchuk, B.G. Weinshenker // Cur. Treat. Opinions neurol. 2005. — Vol. 7, N 3. — P. 173−182.
- Wolswijk, G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodenrdrocyte precursor cells / G. Wolswijk // J. Neuroscience. 1998. — Vol. 18. — P. 601−609.
- Wucherpfennig, K.W. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein / K.W. Wucherpfennig, J.L. Strominger // Cell. 1995. — Vol. 80, N 5. — P. 695 705.
- Yuki, N. Pathogenesis of Guillian-Barre and Miller Fisher syndromes subsequent to Campylobacter jejuni enteritis / N. Yuki // J. Infect. Dis. 1999. -Vol. 52.-P. 99−105.